Table 1 Baseline patient characteristics (n = 78)
Age (years), median (IQR) | 56.4 (48 to 66.75) |
Body Mass Index (kg/m2), median (IQR) | 26.6 (24.4 to 30.2) |
Female | 61 (78.2%) |
Ever Smoked | 47 (60.3%) |
Current smokers | 22 (28.2%) |
Caucasian race | 73 (93.6%) |
*Continuing triple DMARD therapy | 51 (65.4%) |
*Continuing methotrexate | 60 (76.9%) |
*Continuing sulfasalazine | 60 (76.9%) |
*Continuing hydroxychloroquine | 70 (89.7%) |
Initiation of leflunomide with loading dose | 7 (9.0%) |
Anti-CCP antibody (n = 77) | 38 (49.4%) |
Rheumatoid factor | 46 (59.0%) |
Shared epitope (n = 76) | 52 (68.4%) |
Duration of disease prior to initiation of leflunomide (weeks), median (IQR) | 48 (32.3 to 92.1) |
DAS28 (at start of leflunomide therapy), median (IQR) | 5.8 (5.2 to 6.5) |